Therapeutic antibodies elicited by immunization against TNF-α

Nature Biotechnology

Volumn 17, Issue 7, 1999, Pages 666-669

  Dalum, Iben ^a   Butler, Debra M ^b   Jensen, Martin R ^a   Hindersson, Peter ^a   Steinaa, Lucilla ^a   Waterston, Ashita M ^b   Grell, Susanne N ^a   Feldmann, Marc ^b   Elsner, Henrik I ^a   Mouritsen, Søren ^a  

^a M and E Biotech A/S   (Denmark)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Active immunization; Anti TNF ; Autoantibodies; Cachexia; Chronic inflammatory disease; Collagen induced arthritis (CIA); TNF ; Vaccination

Indexed keywords

COLLAGEN; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTHRITIS; ARTICLE; B LYMPHOCYTE; CHRONIC INFLAMMATION; CONTROLLED STUDY; CROHN DISEASE; CROSS REACTION; HELPER CELL; IMMUNIZATION; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CACHEXIA; COLLAGEN; EPITOPES; IMMUNIZATION; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED DBA; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 0033018740     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/10878     Document Type: Article

References (25)

1. Thorbecke, G.J. et al. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc. Natl. Acad. Sci. USA 89, 7375-7379 (1992).
2. Williams, R.O., Feldmann, M. & Maini, R.N. Anti-tumor necrosis factor amelio-rates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 89, 9784-9788 (1992).
3. Williams, R.O., Ghrayeb, J., Feldmann, M. & Maini, R.N. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 84, 433-439 (1995).
4. Neurath, M.F. et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur. J. Immunol. 27, 1743-1750 (1997).
5. Elliott, M.J. et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 36, 1681-1690 (1993).
6. Moreland, L.W. et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337, 141-147 (1997).
7. Targan, S.R. et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 337, 1029-1035 (1997).
8. Elliott, M.J. et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344, 1125-1127 (1994).
9. Sette, A. et al. Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. Nature 328, 395-399 (1987).
10. Shastri, N., Gammon, G., Horvath, S., Miller, A. & Sercarz, E.E. The choice between two distinct T cell determinants within a 23-amino acid region of lysozyme depends on their structural context. J. Immunol. 137, 911-915 (1986).
11. Ruff, M.R. & Gifford, G.E. Purification and physico-chemical characterization of rabbit tumor necrosis factor. J. Immunol. 125, 1671-1677 (1980).
12. Nemazee, D.A. & Burki, K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 337, 562-566 (1989).
13. Goodnow, C.C. et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 334, 676-682 (1988).
14. Dalum, I., Jensen, M.R., Hindersson, P., Elsner, H.I. & Mouritsen, S. Breaking of B cell tolerance toward a highly conserved self protein. J. Immunol. 157, 4796-4804 (1996).
15. Dalum, I. et al. Induction of cross-reactive antibodies against a self protein by immunization with a modified self protein containing a foreign T helper epitope. Mol. Immunol 34, 1113-1120 (1997).
16. Eck, M.J. & Sprang, S.R. The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. J. Biol. Chem. 264, 17595-17605 (1989).
17. Bloom, J.W. Bettencourt, J.D. & Mitra, G. Epitope mapping and functional analysis of three murine IgG1 monoclonal antibodies to human tumor necrosis factor-α. J. Immunol. 151, 2707-2716 (1993).
18. Cerami, A., Ikeda, Y., Le Trang, N., Hotez, P.J., & Beutler, B. Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol. Lett. 11, 173-177 (1985).
19. Staines, N.A. & Wooley, P.H. Collagen arthritis - what can it teach us? Br. J. Rheumatol. 33, 798-807 (1994).
20. Lehmann, P.V., Forsthuber, T., Miller, A. & Sercarz, E.E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358, 155-157 (1992).
21. Pasparakis, M., Alexopoulou, L., Episkopou, V. & Kollias, G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med. 184, 1397-1411 (1996).
22. Rothe, J. et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364, 798-802 (1993).
23. Erickson, S.L. et al. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 372, 560-563 (1994).
24. Panina-Bordignon, P. et al. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19, 2237-2242 (1989).
25. Williams, R.O., Williams, D.G. & Maini, R.N. Anti-type II collagen ELISA. Increased disease specificity following removal of anionic contaminants from salt-fractionated type II collagen. J. Immunol. Methods 147, 93-100 (1992).